- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05970289
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
March 20, 2024 updated by: Brii Biosciences Limited
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
75
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Kingswood, New South Wales, Australia, 2747
- Investigative Site 61001
-
-
Queensland
-
Birtinya, Queensland, Australia, 4575
- Investigative Site 61002
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Investigative Site 61003
-
-
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Investigative Site 86001
-
Beijing, Beijing, China, 100050
- Investigative Site 86001
-
Beijing, Beijing, China, 100069
- Investigative Site 86007
-
-
Chongqing
-
Chongqing, Chongqing, China, 400010
- Investigative Site 86004
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- Investigative Site 86006
-
-
Hong Kong
-
Hong Kong, Hong Kong, China, 999077
- Investigative Site 85201
-
Hong Kong, Hong Kong, China, 999077
- Investigative Site 85202
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Investigative Site 86008
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Investigative Site 86013
-
-
Taiwan
-
Kaohsiung, Taiwan, China, 80756
- Investigative Site 88601
-
Taipei, Taiwan, China, 10041
- Investigative Site 88602
-
Taipei, Taiwan, China, 11217
- Investigative Site 88603
-
-
Zhengjiang
-
Hangzhou, Zhengjiang, China, 310016
- Investigative Site 86011
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Investigative Site 82001
-
Chuncheon-si, Korea, Republic of, 24253
- Investigative Site 82002
-
Daegu, Korea, Republic of, 41566
- Investigative Site 82004
-
Seoul, Korea, Republic of, 6351
- Investigative Site 82003
-
Seoul, Korea, Republic of, 13496
- Investigative Site 82005
-
Soeul, Korea, Republic of, 05505
- Investigative Site 82006
-
-
-
-
-
Singapore, Singapore, 529889
- Investigative Site 65002
-
Singapore, Singapore, 169856
- Investigative Site 65001
-
-
-
-
-
Bangkok, Thailand, 10330
- Investigative Site 66003
-
Chiang Mai, Thailand, 50200
- nvestigative Site 66007
-
Khon Kaen, Thailand, 40002
- Investigative Site 66005
-
Nonthaburi, Thailand, 11000
- Investigative Site 66006
-
Songkhla, Thailand, 90110
- Investigative Site 66008
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female aged 18-60.
- Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.
- Chronic HBV infection for ≥ 6 months.
- On NRTI therapy for at least 6 months.
Exclusion Criteria:
- Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation.
- Significant liver fibrosis or cirrhosis.
- History or evidence of drug or alcohol abuse.
- History of intolerance to SC injection.
- History of chronic liver disease from any cause other than chronic HBV infection.
- History of hepatic decompensation.
- Contraindications to the use of Peg-IFNα.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Participants will receive multiple doses of PEG-IFNα for 48 weeks.
|
PEG-IFNα will be given via subcutaneous injection
Other Names:
|
Experimental: Cohort 2
Participants will receive multiple doses of higher dose level of BRII-835 + PEG-IFNα for 48 weeks.
|
PEG-IFNα will be given via subcutaneous injection
Other Names:
BRII-835 will be given via subcutaneous injection
|
Experimental: Cohort 3
Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks.
|
PEG-IFNα will be given via subcutaneous injection
Other Names:
BRII-835 will be given via subcutaneous injection
|
Experimental: Cohort 4
Participants will receive multiple doses of lower dose level of BRII-835 + PEG-IFNα for 48 weeks (participants who received BRII-179 in a previous study will roll over into this cohort).
|
PEG-IFNα will be given via subcutaneous injection
Other Names:
BRII-835 will be given via subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants with HBsAg loss at end of treatment
Time Frame: Up to Week 48
|
Up to Week 48
|
Proportion of participants with HBsAg loss at 24 weeks post-end of treatment
Time Frame: Up to Week 72
|
Up to Week 72
|
Proportion of participants with treatment-emergent adverse events (TEAEs)
Time Frame: Up to Week 72
|
Up to Week 72
|
Proportion of participants with serious adverse events (SAEs)
Time Frame: Up to Week 72
|
Up to Week 72
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Xiaofei Chen, Brii Biosciences Limited
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 22, 2023
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
February 1, 2026
Study Registration Dates
First Submitted
July 21, 2023
First Submitted That Met QC Criteria
July 21, 2023
First Posted (Actual)
August 1, 2023
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Chronic Disease
- Infections
- Hepatitis B
- Hepatitis
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Herpesviridae Infections
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Interferons
- Interferon-alpha
Other Study ID Numbers
- BRII-835-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis B Virus Infection
-
Enanta Pharmaceuticals, IncTerminatedChronic Hepatitis B Virus InfectionNew Zealand
-
Yangshengtang Co., LtdNot yet recruitingChronic Hepatitis B Virus Infection
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Hoffmann-La RocheTerminatedHepatitis B Virus InfectionUnited Kingdom, Hong Kong, Korea, Republic of, Taiwan, Poland, Bulgaria, New Zealand
-
Sun Yat-sen UniversityRecruitingChronic Hepatitis B Virus InfectionChina
-
Enanta Pharmaceuticals, IncPharmaceutical Research AssociatesCompletedChronic HBV InfectionUnited States, Canada
-
National Taiwan University HospitalPharmaEssentiaRecruitingChronic Hepatitis B Virus InfectionTaiwan
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.RecruitingChronic Hepatitis bChina
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bMoldova, Republic of, Ukraine
Clinical Trials on PEG-IFNα
-
Vir Biotechnology, Inc.Active, not recruitingHepatitis B, ChronicHong Kong, Korea, Republic of, United Kingdom, France, Moldova, Republic of, Romania
-
Vir Biotechnology, Inc.RecruitingHepatitis B, ChronicHong Kong, Korea, Republic of, Malaysia, New Zealand, Taiwan, United Kingdom, Romania, United States, Moldova, Republic of, Canada, Germany, Ukraine
-
Merck Sharp & Dohme LLCNovartis PharmaceuticalsCompletedChronic Hepatitis CUnited States
-
The Second Affiliated Hospital of Chongqing Medical...Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...Not yet recruitingChronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNαChina
-
Beijing 302 HospitalRecruitingChronic Hepatitis BChina
-
Beijing 302 HospitalRecruitingChronic Hepatitis BChina
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
Beijing 302 HospitalUnknown
-
Tasly Tianjin Biopharmaceutical Co., Ltd.Unknown
-
Assembly BiosciencesTerminated